Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) Operating Expenses (2018 - 2025)

Neurogene (NGNE) has disclosed Operating Expenses for 5 consecutive years, with $23.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses rose 7.29% year-over-year to $23.8 million, compared with a TTM value of $97.3 million through Sep 2025, up 47.71%, and an annual FY2024 reading of $83.5 million, up 50.28% over the prior year.
  • Operating Expenses was $23.8 million for Q3 2025 at Neurogene, down from $26.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $26.1 million in Q2 2025 and bottomed at $18.8 million in Q1 2024.